Ali Bazarbachi

1 month ago | nature.com | Arnon Nagler |Nicolaus Kröger |Matthias Stelljes |Johan Maertens |Gesine Bug |Didier Blaise | +3 more

AbstractThe cytogenetic risk category retains a pivotal role in the prediction of prognosis in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT), however, its impact on secondary AML (sAML) is less established. We assessed whether the ELN 2022 cytogenetic risk score predicts outcomes in sAML patients in remission undergoing HSCT from HLA-matched donors performed between 2010 and 2022.

1 month ago | nature.com | Ali Bazarbachi |Didier Blaise |Eva Wagner-Drouet |Jakob Passweg |Ibrahim Yakoub-Agha |Peter Dreger | +3 more

AbstractAllogeneic hematopoietic cell transplantation remains an important curative treatment for patients with acute lymphoblastic leukemia (ALL). Over time, significant progress in transplant and post-transplant care has allowed the delivery of transplant to older patients. We assessed changes over time in characteristics and outcomes in patients ≥60 years with ALL using a dataset from the EBMT registry.

May 1, 2024 | nature.com | Ali Bazarbachi |Jürgen Finke |Nicolaus Kröger |Martin Bornhauser |Friedrich Stölzel |Peter Dreger | +4 more

AbstractSecond allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome.

Mar 26, 2024 | healio.com | Matthew Shinkle |Mindy Valcarcel |Ali Bazarbachi

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Over the last 2 decades, 3-year cumulative relapse incidence decreased among elderly patients with AML. OS and 3-year leukemia-free survival also both improved over the last 2 decades.

Jan 30, 2024 | nature.com | Meral Beksac |Xavier Poiré |Ali Bazarbachi |Thomas Pabst |Jürgen Finke |Inken Hilgendorf | +3 more

AbstractBortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres.